RayKnowChina Research Map
Shortlist

BeijingCapital Medical University

Beijing Ditan Hospital, Capital Medical University

首都医科大学附属北京地坛医院

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Beijing Ditan Hospital, Capital Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌72 papers led
  2. Hepatoblastoma肝母细胞瘤0 papers led
  3. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  4. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  5. Primary biliary cholangitis原发性胆汁性胆管炎11 papers led
  6. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 72 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
72
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 161620212022: 161620222023: 111120232024: 8820242025: 21212025

17 hospitals in Beijing for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

  2. Recruiting
    InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07848750

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologyMedical oncologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led72
  1. Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study.2025Acta oncologica (Stockholm, Sweden)Free full text
  2. Comprehensive Analysis of Oncogenic, Prognostic, and Immunological Roles of FANCD2 in Hepatocellular Carcinoma: A Potential Predictor for Survival and Immunotherapy.2025Biomedical and environmental sciences : BES
  3. Mono-TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First-Line Treatment of Lenvatinib: A Real-World Study.2025Cancer medicineFree full text
  4. Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial.2025Chinese journal of integrative medicineRCT
  5. The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.2025Clinical and experimental medicineFree full text
  6. FoxO1 as a Hub in Immunosenescence Induced by Hepatocellular Carcinoma and the Effect of Yangyin Fuzheng Jiedu Prescription.2025Drug design, development and therapyFree full text
  7. Systemic immune classification related to immune exhaustion evaluates the clinical response of patients with HBV-HCC after transarterial chemoembolization.2025Frontiers in immunologyFree full text
  8. Featured intestinal microbiota associated with hepatocellular carcinoma in various liver disease states.2025Frontiers in immunologyFree full text
  9. Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study.2025Frontiers in immunologyFree full text
  10. Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration.2025Gut microbesFree full text
  11. Mechanism of Jiedu Prescription in Hepatocellular Carcinoma: Integrating Network Pharmacology and Experimental Validation.2025Integrative cancer therapiesFree full text
  12. Value of CD8+ T cell-related genes and IL-6/STAT3 signaling pathway in the prognosis of HCC and experimental investigation.2025International journal of biological macromolecules
  13. Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.2025International journal of nanomedicineFree full text
  14. Application of Nanotechnology in TACE Treatment of Liver Cancer.2025International journal of nanomedicineFree full text
  15. Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer.2025International journal of nanomedicineFree full text
  16. Machine learning-based hepatocellular carcinoma risk prediction model for patients with HBV-related compensated advanced chronic liver disease.2025Journal of cancer research and clinical oncologyFree full text
  17. Mechanism of Shashen-Maidong herb pair in treating hepatocellular carcinoma using network pharmacology and experimental validation.2025Journal of ethnopharmacology
  18. Loss of FAM172A gene prompts cell proliferation in liver regeneration.2025Molecular and cellular biochemistry
  19. Clinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up.2025Virologica SinicaFree full text
  20. CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma.2025World journal of gastroenterologyFree full text
  21. Machine learning model using immune indicators to predict outcomes in early liver cancer.2025World journal of gastroenterologyFree full text
  22. Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.2024Cancer scienceFree full text
  23. Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Astragalus-Atractylodes Herb Pair in Treating Hepatocellular Carcinoma.2024Drug design, development and therapyFree full text
  24. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.2024Frontiers in immunologyFree full text
  25. Prognostic value of CD8+T cells related genes and exhaustion regulation of Notch signaling pathway in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  26. Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors.2024Human vaccines & immunotherapeuticsFree full text
  27. A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma.2024Scandinavian journal of gastroenterology
  28. Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma.2024VirulenceFree full text
  29. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.2024World journal of gastroenterologyFree full text
  30. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.2023BMC cancerFree full text
  31. Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.2023BMC cancerFree full text
  32. The m6A/m5C/m1A regulator genes signature reveals the prognosis and is related with immune microenvironment for hepatocellular carcinoma.2023BMC gastroenterologyFree full text
  33. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.2023Cancer immunology, immunotherapy : CIIFree full text
  34. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma.2023Cancer medicineFree full text
  35. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.2023Cancer medicineFree full text
  36. D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.2023Clinics and research in hepatology and gastroenterology
  37. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.2023European journal of medical researchFree full text
  38. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.2023Frontiers in cellular and infection microbiologyFree full text
  39. S100A11 Promotes Metastasis via AKT and ERK Signaling Pathways and Has a Diagnostic Role in Hepatocellular Carcinoma.2023International journal of medical sciencesFree full text
  40. Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma.2023The oncologistFree full text
  41. Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts.2022Annals of hepatology
  42. Long-term outcomes of hepatectomy or radiofrequency ablation associated with splenectomy for the treatment of hepatocellular carcinoma and esophagogastric variceal bleeding.2022Asian journal of surgery
  43. Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.2022BMC cancerFree full text
  44. The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model.2022BMC cancerFree full text
  45. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.2022Cancer biology & therapyFree full text
  46. Effect of valproic acid on extrinsic and intrinsic apoptotic pathways, cell viability and apoptosis in hepatocellular carcinoma PLC/PRF5 cell line.2022Cellular and molecular biology (Noisy-le-Grand, France)
  47. Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis.2022Frontiers in cellular and infection microbiologyFree full text
  48. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  49. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.2022Frontiers in immunologyFree full text
  50. Safety and efficacy of percutaneous microwave ablation using combined computed tomography and ultrasound-guided imaging in patients with hepatocellular carcinoma: A retrospective study.2022Journal of cancer research and therapeutics
  51. Liver abscess after microwave ablation of hepatocellular carcinoma caused by Clostridium perfringens.2022Journal of infection in developing countries
  52. Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  53. Effect of decoction of Fuzheng Jiedu Xiaoji formula plus chemoembolization on primary liver cancer in patients.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen panRCTFree full text
  54. The association between several autophagy-related genes and their prognostic values in hepatocellular carcinoma: a study on the foundation of TCGA, GEPIA and HPA databases.2022Molecular biology reports
  55. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.2022Technology in cancer research & treatmentFree full text
  56. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.2022The Cochrane database of systematic reviewsFree full text
  57. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy.2021BMC cancerFree full text
  58. Gene Polymorphism of MUC15, MMP14, BRAF, and COL1A1 Is Associated with Capsule Formation in Hepatocellular Carcinoma.2021Canadian journal of gastroenterology & hepatologyFree full text
  59. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.2021CancerRCT
  60. A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer.2021Cancer immunology research
  61. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.2021Clinics and research in hepatology and gastroenterology
  62. Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.2021European journal of gastroenterology & hepatology
  63. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  64. Prognostic value of liver stiffness measurement in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation: a meta-analysis.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  65. Effect of microwave ablation on platelet and coagulation function in patients with BCLC-A hepatocellular carcinoma.2021Journal of cancer research and therapeutics
  66. TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma.2021OncoimmunologyFree full text
  67. Yangyin Fuzheng Jiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  68. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.2021Phytomedicine : international journal of phytotherapy and phytopharmacologyRCT
  69. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation.2021Reproductive biology
  70. The development of a predictive risk model on post-ablation hemobilia: a multicenter matched case-control study.2021The British journal of radiologyFree full text
  71. Hepatocellular carcinoma with type II-III portal vein tumour thrombosis: treatment using transarterial chemoembolisation and microwave ablation.2021The British journal of radiologyFree full text
  72. Imaging features and outcomes in patients with ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization: a retrospective clinical study.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)4
  1. [Exploring the advantages of traditional Chinese medicine and dual-anti therapy for liver cirrhosis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Fuzheng Huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils/lymphocytes].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Effects of anti-liver fibrosis treatment on the occurrence of liver cancer in patients with hepatitis B-related liver cirrhosis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [The progress and challenges in immunotherapy for the difficulty- to- treat liver diseases].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status13
  1. Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)Status unknownNCT05152498Lead sponsorEarly phase 1Start 2021-01
  2. A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and CirrhosisStatus unknownNCT04301908Lead sponsorStart 2020-04
  3. Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)Status unknownNCT05088733Lead sponsorEarly phase 1Start 2020-07
  4. Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter RatioStatus unknownNCT05154812Lead sponsorEarly phase 1Start 2020-10
  5. Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTTStatus unknownNCT04127396Lead sponsorPhase 4Start 2019-09
  6. Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in DiameterCompletedNCT04264962Lead sponsorEarly phase 1Start 2017-01
  7. Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular CarcinomaCompletedNCT02927626Lead sponsorEarly phase 1Start 2016-08
  8. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  9. InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular CarcinomaRecruitingNCT07848750Study siteStart 2026-06
  10. A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07713290Study sitePhase 1Start 2025-04
  11. Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular CarcinomaCompletedNCT07845266Study sitePhase 1Start 2024-04
  12. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  13. Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCCStatus unknownNCT04157140Study sitePhase 2Start 2019-11

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Beijing for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Beijing for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 11 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 3.7%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 332025

15 hospitals in Beijing for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyPathology / laboratory medicine
Papers it led11
  1. Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis.2026Annals of hepatology
  2. Systemic inflammatory response index: a novel predictor for cardiovascular disease risk in patients with primary biliary cholangitis.2025European journal of medical research
  3. Real-world performance of transient elastography in assessing advanced fibrosis in Chinese patients with primary biliary cholangitis.2025World journal of gastroenterology
  4. Multi-omics analysis reveals gut microbiota-metabolite interactions and their association with liver function in autoimmune overlap syndrome.2025World journal of gastroenterology
  5. High C-reactive protein-to-albumin ratio levels are associated with osteoporosis in patients with primary biliary cholangitis.2024Frontiers in endocrinology
  6. Machine learning-based characterization of the gut microbiome associated with the progression of primary biliary cholangitis to cirrhosis.2024Microbes and infection
  7. Clinical significance of serum antinuclear antibodies in patients with autoimmune hepatitis and comorbidity.2023Clinical and experimental medicine
  8. Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.2023World journal of gastroenterology
  9. Methylation of the HCBP6 promoter is associated with primary biliary cholangitis pathogenesis.2022Biochemical and biophysical research communications
  10. The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism.2022Frontiers in immunology
  11. Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study.2021Canadian journal of gastroenterology & hepatology
Chinese-language papers (not in the count)1
  1. [Clinicopathological features of Sjogren's syndrome complicated with liver injury].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)2
  1. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.2018European journal of gastroenterology & hepatology
  2. [Effect of ursodeoxycholic acid with traditional Chinese medicine on biochemical response in patients with primary biliary cholangitis: a real-world cohort study].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status3
  1. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  2. Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease ProgressionNot yet recruitingNCT07733882Study siteStart 2026-08
  3. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

10 hospitals in Beijing for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Study sitePhase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京地坛医院

Beijing Ditan Hospital, Capital Medical University

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Beijing Ditan Hospital; Beijing Ditan Hospital Affiliated to Capital Medical University; Beijing Ditan Hospital Capital Medical University; Capital Medical University Affiliated Beijing Ditan Hospital; Capital Medical University Beijing Ditan Hospital; Beijing Ditan Hosipital; China Capital Medical University Beijing Ditan Hospital; Beijing First Infectious Diseases Hospital

Suggest a correctionDownload the data